BIT Science Discussion, page-120

Dr Michelle Miller, BSc, MSc, PhD GCertAppFin (Finsia)
Chief Executive Officer and Managing Director
Dr Miller has worked for over 20 years in the bioscience industry, with extensive experience in commercial development of early to mid stage technologies. She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development. Her experience includes several years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials.
She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.

Dr Miller was appointed as Managing Director on 21 June 2002.

Dr Susan M Pond AM, MD DSc, FTSE FAHMS
Independent and Non-Executive Director
Dr Pond has a strong scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as Chairman and Managing Director of Johnson & Johnson Research Pty Limited (2003-2009). Most recently, she was Director of the University of Sydney Nano Institute from February 2017 – April 2018. She has held many previous Board positions including as Executive Director of Johnson & Johnson Pty Limited and Non-executive Director and Chairman of AusBiotech Limited, Director of Australian Nuclear Science and Technology Orgnaisation and Australian Academy of Technological Sciences and Engineering (ATSE) and Board member of Commercialisation Australia and Innovation Australia.

Dr Pond is currently on the Boards of the Wound Management Innovation Cooperative Research Centre and Vectus Biosystems Ltd. She is a Fellow of the Australian Institute of Company Directors, the Academy of Technological Sciences & Engineering and the Academy of Health and Medical Sciences.

Dr Pond holds a first class honours degree in Bachelor of Medicine and Surgery from the University of Sydney and a Doctor of Medicine degree from the University of New South Wales. She obtained specialist clinical credentials in internal medicine, clinical pharmacology and clinical toxicology and has held academic appointments at the University of California, San Francisco and the University of Queensland before joining industry.

Dr Pond was appointed as a Director on 7 March 2012.